 |
|
|
| |
IMPAACT P1110: RALTEGRAVIR PHARMACOKINETICS AND SAFETY IN HIV-1 EXPOSED NEONATES: DOSE-FINDING STUDY
|
| |
| |
Reported by Jules Levin
CROI 2017 Feb 14-16 Seattle, WA
Diana F. Clarke1, Edward P. Acosta2, Anne Chain3, Mae Cababasay4, JiaJia Wang4, Hedy Teppler3, Betsy Smith5, Rohan Hazra6, 7Stephanie Popson, 7Bobbie Graham, 8Kat Calabrese, 9Yvonne Bryson, 10Stephen A. Spector, 11Jos Lommerse, 12Mark Mirochnick, and the IMPAACT P1110 Protocol Team 1Boston Medical Center, Boston, MA, United States; U of Alabama at Birmingham, Birmingham, AL; 3Merck Research Laboratories; 4Statistical and Data Analysis Center, Harvard School of Public Health, Boston, MA; 5NIH, NIAID, Division of AIDS, Bethesda, MD; 6Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH, Bethesda, MD; FSTRF, Buffalo, NY; 8 FHI 360, Durham, NC; 9UCLA, Los Angeles, CA; 10 UCSD, La Jolla, CA; 11Certara, Oss, The Netherlands; 12Boston University School of Medicine, Boston, MA
|
| |
|
|
|
|
|
